Metabolic

Latest Features

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Physical Activity for Diabetes: ADA Updated Guidelines

Physical Activity for Diabetes: ADA Updated Guidelines

Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.

Hope for Heart Failure in Thyroid Hormone Therapy

Hope for Heart Failure in Thyroid Hormone Therapy

Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Reducing the Progression of Coronary Heart Disease With Estradiol

Reducing the Progression of Coronary Heart Disease With Estradiol

In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Vitamin D may influence cardiovascular disease risk via its effect on lipid levels.

Latest News

Systolic Blood Pressure Variability Independently Predicts CV Events and Death in Diabetes

Systolic Blood Pressure Variability Independently Predicts CV Events and Death in Diabetes

Visit-to-visit systolic blood pressure variability may be a better predictor of cardiovascular events and death than traditional risk factors.

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

American Diabetes Association presented a study that Canagliflozin could possibly decrease cardiovascular stress in older patients with type 2 diabetes.

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

Two studies found that extended-release naltrexone/bupropion did not increase cardiovascular risks for patients with type 2 diabetes.

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

Kidney and eye events in type 2 diabetes were reduced with more intensive glucose control.

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.

Glucagon-Like Peptide-1 Receptor Agonists May Lower Cardiovascular Risk in Type 2 Diabetes

Glucagon-Like Peptide-1 Receptor Agonists May Lower Cardiovascular Risk in Type 2 Diabetes

Glucagon-like peptide-1 receptor agonist therapy was associated with lower risk for acute MI, stroke, and all-cause mortality.

Frequent Hot Flashes Give Cardiovascular Insight In Young Women

Frequent Hot Flashes Give Cardiovascular Insight In Young Women

Frequent hot flashes in younger women were linked to endothelial function, providing more insight into the cardiovascular disease risk status of patients.

Overweight/Obesity Affects Brain Function in Type 2 Diabetes

Overweight/Obesity Affects Brain Function in Type 2 Diabetes

Overweight or obese patients with type 2 diabetes mellitus are more likely to show severe and progressive brain function and cognition abnormalities.

Low HbA1c After Metformin Initiation Lowers CV Risks in T2D Patients

Low HbA1c After Metformin Initiation Lowers CV Risks in T2D Patients

A large, initial reduction in hemoglobin A1c (HbA1c) and achievement of low HbA1c levels 6 months after metformin initiation lowered the risk for cardiovascular events and death in patients with type 2 diabetes.

Severe Hypoglycemia Affects Short-Term Mortality in Type 2 Diabetes

Severe Hypoglycemia Affects Short-Term Mortality in Type 2 Diabetes

The majority of patients with diabetes requiring hospitalization for severe hypoglycemia were patients with type 2 diabetes.

Sign Up for Free e-Newsletters